<DOC>
	<DOC>NCT01790893</DOC>
	<brief_summary>The purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed Ocular Histoplasmosis Syndrome.</brief_summary>
	<brief_title>Treatment for Presumed Ocular Histoplasmosis</brief_title>
	<detailed_description />
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Histoplasmosis</mesh_term>
	<criteria>Active choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis demonstrated by active leakage on fluorescein angiography with spectal domain OCT evidence of subretinal or intraretinal fluid or PED. Active CNV may also be defined as demonstrating active subretinal hemorrhage. ETDRS Best corrected visual acuity 20/2020/320. willing and able to comply with all study clinic visits and study related procedures. Willing to use and practice more than one form of contraceptives during the 13 month study for male and female. Provide signed informed consent Able to understand and complete study related questionnaires Under 18 years of age CNV due to other causes than Presumed Ocular Histoplasmosis Previous treatment in the study eye within 6 months prior to Day 1 More than 5 Intravitreal injections of antiVEGF therapy within previous 12 months Any clinical evidence of any other ocular condition other than Ocular histoplasmosis History of allergy to fluorescein Pregnant( or planning on becoming pregnant within the next 13 months) or breast feeding women Sexually Active Men or Women who are NOT willing to practice more than one form of contraceptives during the next 13 months. Anticipated or previous (within previous 3 months) systemic antiVEGF therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Histoplasmosis</keyword>
</DOC>